No Data
No Data
Barclays Maintains Medtronic(MDT.US) With Buy Rating, Raises Target Price to $109
Unusual Options Activity: SPOT, MOD and Others Attract Market Bets, SPOT V/OI Ratio Reaches 90.4
With 85% Institutional Ownership, Medtronic Plc (NYSE:MDT) Is a Favorite Amongst the Big Guns
Barclays Adjusts Price Target on Medtronic to $109 From $105
Australia Diabetes Market Forecasts and Company Analysis 2024-2032, Novo Nordisk, Eli Lilly, Roche, Abbott Laboratories, Insuletn, Dexcom, Medtronic, Ypsomed
S&P 500, Dow Hit Records Right After Open | Live Stock
No Data
No Data